In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Axcan Pharma gets rights to Merz's cirrhosis therapeutic

Executive Summary

Axcan Pharma has received an exclusive license from Merz Pharmaceuticals to develop injectable and oral granule formulations that contain L-ornithine and L-aspartate. The drugs are used to treat hepatic encephalopathy (HE) that may accompany early- to late-stage liver cirrhosis.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register